

Supporting Information

Designing Michaelases: Exploration of novel protein scaffolds for iminium biocatalysis

Alejandro Gran-Scheuch,^a Stefanie Hanreich,^a Iris Keizer,^a Jaap Harteveld,^a Eelco Ruitjer^a & Ivana Drienovská^{a,*}

Biocatalysis is becoming a powerful and sustainable alternative for asymmetric catalysis. However, enzymes are often restricted to metabolic and less complex reactivities. This can be addressed by protein engineering, such as incorporating new-to-nature functional groups into proteins through the so-called expansion of the genetic code to produce artificial enzymes. Selecting a suitable protein scaffold is a challenging task that plays a key role in designing artificial enzymes. In this work, we explored different protein scaffolds for an abiological model of iminium ion catalysis, Michael addition of nitromethane into *E*-cinnamaldehyde. We studied scaffolds looking for open hydrophobic pockets and enzymes with described binding sites for the targeted substrate. The proteins were expressed and variants harboring functional amine groups —lysine, *p*-aminophenylalanine, or *N*⁶-(*D*-prolyl)-*L*-lysine— were analyzed toward the model reaction. Among the newly identified scaffolds, a thermophilic ene-reductase from *Thermoanaerobacter pseudethanolicus* exhibited to be the most promising biomolecular scaffold for this reaction.

Table of content

Amino acid sequences of scaffolds	2
Schemes	3
Supporting table	4
Supporting figures	6

^a Department of Chemistry and Pharmaceutical Sciences, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands. *E-mail: i.drienovska@vu.nl

Amino Acid Sequences of Selected Scaffolds

LmrR (NCBI A2R136)

GAEIPKE**M**LRAQTN**V**ILLNLVKQGDNYVYGI**I**KQVKEASNGEMELNEATLYTIFDRLEQDGI**I**SSYWGDESQGGRRKYRLTEIGHEN**M**RLAFE
SWSRVDKI**I**ENLEANKKSEAIKSRGGSGGGSHHHHHH*

BbmrR (NCBI WP_171505753)

MDETLNNSDLVRG**S**IDTII**L**SVLLTGDNYGYQ**I**IKEIYRKSQNR**F**ELKEPTLYSSLRLEKQKMIESYWGEETQGGRRKYYSITELGRELYRTN
CAEWELARNLIDRLIRVEKDVEERLEHHHHHHH*

CdmrR (NCBI WP_020156622)

MNGKISADLLRGHTDTI**V**LSILMQGDHYGYE**I**YKTILEKTEGLYELKEATLYSSYKRLEKEGCI**I**AYWGDETQGGRRKYRITEKGRQYYQNK
ADWEFTKKILNKLLGEEQGLEHHHHHHH*

TbmrR (NCBI HHX23360)

MGNTISTDLIRGHTDTI**L**NLVLRQGDSYGYE**I**YKK**I**IELSGNQYELKEATLYTAFRRLEQDGYVWSYWGDETQGGRRKYRITDEGKKFYEQSK
HAWDFAKGVLDKLIKGGLDNAKDLEHHHHHHH*

AtRegR (NCBI AtRegR)

MSRKEQ**I**IEVAMKLF**A**EKG**Y**HATSMQ**E**IAEHSRLAKGSLYNYFKSKEE**I**VL**S**IFQYHYDQ**L**FQQFARIASDRSLTAREKFLKQLSLQIEAFEKH
KEIVQM**H**MGDHAQK**V**SE**D**HALVLRIRSHLFDWY**I**QSFIDMYGERIRPFVLDCAIMLNGMLKEYLFFALFEKQSF**F**QRLAPFLMERLDALVDS
LQHDMP**L**IRHDAKA**E**KARALALIDEMIEEARD**D**HTMDLLKQ**L**KEEMERDEPRKA**I**VEAFLLYLQQSDMRQFVPALRAALAL**L**EHHHHHH*

TmRegR (NCBI WP_004080830)

MSSETRRK**I**LEAARKAF**S**KYGYDGVSME**E**IAREAGVKKAL**I**Y**Y**YFPSKDKLFEEVWREALEE**L**ESH**L**FAVTEETNSYFAK**I**KKFLKSYVD**F**VLN
KTVLNE**I**IEKEKSTVR**F**EE**E**KWSKLRER**Y**ESF**I**KRVEELIEEGKKQNYVYKDLD**S**RAAAELIVNSFGDV**P**KDKRLLQNIQEMILRGLLN**V**KTEE
GRLEHHHHHHH*

VAO (NCBI P56216)

MSKTQEF**R**PLTLPPKLSLSD**F**NEFIQDI**I**IRIVGSENVE**V**ISSKDQIVDGSYMKP**T**HT**H**DP**H**HVMDQDYFLAS**A**IVAPRNVADVQS**I**VGLANK**F**S
FPLWPI**S**IGRNS**G**YGGAA**P**RVSGSVVLDMGKNMNRVLEVNVEGAYCVVEPGVTYHDLHNYLEANNLRDKLWLDV**P****D**LGGGSVLGNAVERGV**G****Y**T
PYGDHMMHSGMEVVLANGE**L**LRTGMGALPD**P**KRPETMGLKPEDQ**P**WSK**I**AHLFPYGF**G**PYIDGLFSQSNMGIVTKIGIWLM**P**NPRGYQSY**L**IT
LPKDGDLKQAVDI**I**RPLRLGMALQNVPT**I****R**HILLDAAVLGDKRSYSSRTEPLSDEELDK**I**AKQLNLGRWNFYGALYGPEPIRRVLWETIKDA**F**S
AIPGVKFY**F**PE**D**TPENS**V**LRV**R**DKTMQGIPT**Y**DEL**K**WIDWL**P**NGA**H**LFFSP**I**AKVSGEDAMMQYAVTKKRCQ**E**AGLDFIGTFT**V**GMRE**M**HH**I**VC
IVFNKKDL**I**QKRKVQWLMRT**L**IDDC**A**ANGWGEYR**T**HLAFMDQIMETYNWN**N**SSFLRFNEVLKNAVD**P**NG**I**IAPGKSGVWPSQY**S**HVTWKLLE**H**H
HHHH*



TOYE (NCBI 3KRU)

MSILHMP**L**KIKDITIKNRIMMS**P**CM**M****Y**SASTDGM**P**NDWHIVHYATRAIGGVGLIMQEATAVESRGR**I**TDHDLGIWNDEQVKELKKIVDICKANG
AVMG**I**QLAHAGRKCNISYEDVVG**P**SP**I**KAGDRYK**L**PRELSVEE**I**KSIVKAFGEAAK**R**ANLAGYDVVE**I**HA**A**H**G****Y**LIHEFLSPLSNKRKDEY**G**NS
IENRARFLIEVIDEVRKNWPEN**K**PIFVRVSADDYMEGGINIDMMVEYINMIKDKVDLIDVSS**G**LLNVDINLYPGYQV**K**YAETIKKRCNIK**T**SA
VGLIT**T**QELAE**E**ILSNERADLVALGRELLRN**P**YWVLHTYTSKEDWPKQYERAFKKLEHHHHHHH*

EncP (NCBI AAF81735)

MTFVIELDMNVTL**D**QLEDAARQ**R**TPVELSAPVRSRVRASRDVLVKFVQDERVI**Y**GVNTSMGGFVDHLVPVSQARQLQENLINAVATNVGAYLDD
TTARTIMLSRIVSLARGNSA**I**TPANLDK**L**VAVLNAGIVPC**I**PEKGS**L**GTSGDLG**L**PLAAIALVCAGQWKARYNGQIMPGRQAL**S**EAGVE**P**MELSY
KDGLAL**I****N**GTSGMVGLGT**M**VLQAAR**L**VDRYLQVSAL**S**VEGLAGMT**K**PFDP**R**VHG**V**KPHRGQRQVASRLWEGLADSHLAVNELDTEQTLAGE**M**G
TVAKAGSLAIEDAYS**I**KCT**P**QILGPVVDVLD**R**IGATLQDELNSSNDNP**I**VLPEEA**E**VFNHNGHFHGQYVAMAMDH**L**NMALATVTNLANRRVDR**F**L
DKSNSNGLPAFLCREDPGLRLGLMG**G**QFMTAS**I**TAETRTLT**I**PM**S**VQSLTSTAD**F**QDIVSFGFVAARRAREVLTNAAYV**V**AFELL**C**ACQAVDIR
GADKLSS**F**TRPLYERTRK**I**VPFFDRDETITDYVEK**L**AADLIAGEPVDA**A**VAAHLEHHHHHHH*

Schemes

Scheme S1. Staudinger reduction of *pAzF* to *pAF* using Tris(2-carboxyethyl)phosphine (TCEP).

Scheme S2. Synthetic route for the synthesis of Cbz-L-Lys-OMe.

methyl (2s)-6-amino-2-(((benzyloxy)carbonyl)amino)hexanoate (Cbz-L-Lys-OMe)

Cbz-Lys-OH (25.00 g, 89.18 mmol, 1.00 eq) was dissolved in MeOH (270 mL, 0.33 M) and cooled to 0 °C. SOCl_2 (7.2 mL, 98.10 mmol, 1.10 eq) was added dropwise. The ice bath was removed, and the mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC. After completion, the reaction mixture was concentrated to afford the crude product as a clear oil. The product was directly used in the next step without further purification.

Supporting table

Table S1. List of primers used in this study. Mutations are highlighted in red.

Entry	Name	Oligo DNA sequence (5')
1	LmrR_V15TAG_fw	GCT CAA ACC AAT TAG ATC CTG CTG AAT
2	LmrR_V15TAG_rv	ATT CAG CAG GAT CTA ATT GGT TTG AGC
3	LmrR_M8TAG_fw	C CCG AAA GAA TAG CTG CGT GCT CAA AC
4	LmrR_M8TAG_rv	CAG CTA TTC TTT CGG GAT TTC GGC ACC
5	LmrR_M89TAG_fw	AC TAG CGC CTG GCG TTC GAA TCC
6	LmrR_M89TAG_rv	GC CAG GCG CTA GTT TTC ATG GCC GAT TTC
7	LmrR_V15K_fw	GT GCT CAA ACC AAT AAA ATC CTG CTG AAT GTC
8	LmrR_V15K_rv	ATT GGT TTG AGC ACG CAG CAT TTC TTT CG
9	LmrR_M8K_fw	C CCG AAA GAA AAA CTG CGT GCT CAA ACC
10	LmrR_M8K_rv	G CAG TTT TTC TTT CGG GAT TTC GGC ACC
11	LmrR_M89K_fw	C AAA CGC CTG GCG TTC GAA TCC TG
12	LmrR_M89K_rv	CGC CAG GCG TTT GTT TTC ATG GCC GAT TTC
13	BbmrR_S14TAG_fw	GTT CGC GGG TAG ATA GAC ACA ATT ATT CTG
14	BbmrR_S14TAG_rv	T CTA CCC GCG AAC TAA GTC GCT GTT ATT G
15	BbmrR_S14K_fw	GTT CGC GGG AAA ATA GAC ACA ATT ATT CTG TC
16	BbmrR_S14K_rv	T TTT CCC GCG AAC TAA GTC GCT GTT ATT GAG
17	VAO_H61T_fw	CAC GAT CCA ACC CAC GTA ATG GAC CAA G
18	VAO_H61T_rv	G GGT TGG ATC GTG GGT GTG AGT AGG
19	VAO_D170TAG_fw	CCC TAG TTG GGC GGC GGC TCT G
20	VAO_D170TAG_rv	C GCC CAA CTA GGG TAC GTC TAA CCA AAG
21	VAO_L171TAG_fw	C GAT TAG GGC GGC GGC TCT GTG
22	VAO_L171TAG_rv	GCC GCC CTA ATC GGG TAC GTC TAAC
23	VAO_Y187TAG_fw	G GTC GGT TAG ACC CCT TAC GGT GAC
24	VAO_Y187TAG_rv	G GGT CTA ACC GAC CCC ACG CTC
25	VAO_H422TAG_fw	C AAC GGA GCC TAG CTG TTC TTC TCT CC
26	VAO_H422TAG_rv	G CTA GGC TCC GTT GGG TAA CCA ATC G
27	VAO_D170K_fw	CCC AAATTGGGCGGCGGGTCTG
28	VAO_D170K_rv	CGCCCAATTTGGGTACGTCTAACCAAAG
29	VAO_L171K_fw	CC GAT AAA GGC GGC GGC TCT GTG
30	VAO_L171K_rv	CC GCC TTT ATC GGG TAC GTC TAA CC
31	VAO_Y187K_fw	G GTC GGT AAA ACC CCT TAC GGT GAC
32	VAO_Y187K_rv	GG GGT TTT ACC GAC CCC ACG CTC
33	VAO_H422K_fw	C AAC GGA GCC AAA CTG TTC TTC TCT CC
34	VAO_H422K_rv	G TTT GGC TCC GTT GGG TAA CCA ATC G
35	TOYE_Y27TAG_fw	G TAG AGC GCC AGT ACC GAT GGG ATG
36	TOYE_Y27TAG_rv	ACT GGC GCT CTA CAT ACA CAT GGG TGA C
37	TOYE_I67TAG_fw	CGC GGT CGT TAG ACA GAT CAT GAT CTT GG

38	TOYE_I67TAG_rv	T CTA ACG ACC GCG AGA TTC TAC TGC CGT TG
39	TOYE_Y168TAG_fw	CG GCT CAC GGC TAG CTG ATA CAT GAA TTT C
40	TOYE_Y168TAG_rv	G CTA GCC GTG AGC CGC ATG GAT TTC
41	TOYE_Y27K_fw	G AAA AGC GCC AGT ACC GAT GGG ATG
42	TOYE_Y27K_rv	ACT GGC GCT TTT CAT ACA CAT GGG TGAC
43	TOYE_I67K_fw	CGC GGT CGT AAA ACA GAT CAT GAT CTT GG
44	TOYE_I67K_rv	T TTT ACG ACC GCG AGA TTC TAC TGC CGT TG
45	TOYE_Y168K_fw	CG GCT CAC GGC AAA CTG ATA CAT GAA TTT C
46	TOYE_Y168K_rv	G TTT GCC GTG AGC CGC ATG GAT TTC
47	EncP_Y54TAG_fw	GAA CGG GTA ATA TAG GGC GTA AAC ACA TCC
48	EncP_Y54TAG_rv	ATA TTA CCC GTT CAT CCT GTA CGA ATT TAA CCA AC
49	EncP_N196TAG_fw	G CAA GCG TAG CGT AGA TTG GTC GAT CG
50	EncP_N196TAG_rv	ACG CTA CGC TTG CAG CAC CAT TGT TCC
51	EncP_Y54K_fw	G CCG AAA TCA CAA GCG CGG CAG C
52	EncP_Y54K_rv	GC TTG TGA TTT CGG CAC CAG ATG ATC AAC
53	EncP_N196K_fw	G CAA GCG AAA CGT AGA TTG GTC GAT CG
54	EncP_N196K_rv	ACG TTT CGC TTG CAG CAC CAT TGT TCC

Supporting Figures




Figure S1. Pocket-guided search of scaffolds. LmrR and QacR were used as sequence templates. After an initial search, aberrant sequences were manually discarded. Redundant sequences were discarded with a 90% cut-off. Sequence diversity was analyzed by a cladogram. Templates are indicated with a blue arrow.

SDS-PAGE analysis

For SDS-PAGE analysis of all samples a PageRuler™ Prestained Protein Ladder (Thermo Scientific™) marker from 10 to 180 kDa was used. For all SDS-PAGEs, abbreviations stands for: M, Marker; CE, cell-extract; CFE, cell-free extract; FT, flow-through; W, wash with 40 mM imidazole, E, elution fraction and C, concentrated sample, IP, input.




Figure S2. SDS-PAGE of selected scaffolds. Purifications of scaffolds were done by immobilized metal affinity chromatography (Ni^{+2} -NTA) and affinity purification for LmrR (Strep-tag II). a) Proteins identified from pocket-guided search, BbmrR (MW 15 kDa), CdmrR (MW 15 kDa), AtRegR (MW 30 kDa), TmbrR (MW 15 kDa) and TmRegR (MW 30 kDa), 1: CE, 2: CFE, 3: insoluble fraction and 4: E. b) LmrR, MW 15 kDa, c) BbmrR MW 15 kDa, d) VAO_H61T, MW 64 kDa, e) TOYE, MW 38 kDa and f) EncP_R299K, MW 57 kDa.




Figure S3. LC-MS analysis of selected scaffolds. Mass spectrum of components (left panel) and deconvoluted ion set (right panel) of each purified scaffold. a) LmrR, M_{calc} : 15,102 Da; M_{obs} : 14,973 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 129$ Da). b) BbmrR, M_{calc} : 15,181 Da; M_{obs} : 15,182 Da. c) VAO_H61T, M_{calc} : 64,064 Da; M_{obs} : 63,934 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 129$ Da). d) TOYE, M_{calc} : 39,238 Da; M_{obs} : 39,110. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 128$ Da) and e) EncP_R299K, M_{calc} : 57,453; M_{obs} : 57,320. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 133$ Da).




Figure S4. Size-exclusion chromatography of BbmrR. The oligomeric state of BbmrR (red line) was determined via analytical size-exclusion chromatography on a Superdex 200 10/300 gel filtration column. For comparison, LmrR (black line), described as dimer ca. 30 kDa,^[21] was evaluated in the same conditions.



Figure S5. Multiple sequence alignment. Preliminary amino acidic sequence analysis was performed using the sequence of LmrR and a selected set of LmrR-like proteins. Analysis was performed Multiple Sequence Comparison by Log-Expectation (MUSCLE) algorithm using Geneious Prime® 2021.2.2. with ClustalW and UPGMB iteration methods.




Figure S6. SDS-PAGE of lysine and *pAz* variants. Purifications of scaffolds were done by immobilized metal affinity chromatography (Ni^{2+} -NTA) and affinity purification for LmrR variants (Strep-tag II) a) LmrR variants ca. MW 15 kDa, b) BbmrR MW 15 kDa, c) VAO_H61T, MW 64 kDa, d) EncP_R299K, MW 57 kDa and TOYE, MW 38 kDa.




Figure S6. SDS-PAGE of lysine and *pAzF* variants. Continuation.




Figure S7. LC-MS analysis of lysine and pAF LmrR variants. Mass spectrum of components (left panel) and deconvoluted ion set (right panel) of each purified scaffold. a) LmrR_M8K. M_{calc} : 15,025 Da; M_{obs} : 14,617 Da. Difference in mass between peaks corresponds to N-terminal methionine and histidine cleavage (Δ 407Da). b) LmrR_V15K. M_{calc} : 15,057 Da; M_{obs} : 14,652 Da. Difference in mass between peaks corresponds to N-terminal methionine and histidine cleavage (Δ 407Da). c) LmrR_M89K. M_{calc} : 15,025 Da; M_{obs} : 14,617 Da. Difference in mass between peaks corresponds to N-terminal methionine and histidine cleavage (Δ 407Da). d) LmrR_M8pAF. M_{calc} : 15,133 Da; M_{obs} : 15,002 Da. Difference in mass corresponds to N-terminal methionine cleavage (Δ 129 Da). e) LmrR_V15pAF. M_{calc} : 15,165 Da; M_{obs} : 15,033 Da. Difference in mass corresponds to N-terminal methionine cleavage (Δ 132 Da). f) LmrR_M89pAF. M_{calc} : 15,133 Da; M_{obs} : 15,000 Da. Difference in mass corresponds to N-terminal methionine cleavage (Δ 132 Da).




Figure S8. LC-MS analysis of lysine and *pAF* BbmrR variants. Mass spectrum of components (left panel) and deconvoluted ion set (right panel) of each purified scaffold. BbmrR_S14K. M_{calc} : 15,222 Da; M_{obs} : 15,219 Da. BbmrR_S14*pAF*. M_{calc} : 15,256 Da ; M_{obs} : 15,283 Da. The difference in mass between the two peaks corresponds to an incomplete reduction of *pAzF* to *pAF* ($\Delta 26$ Da).




Figure S9. LC-MS analysis of lysine and pAF VAO_H61T variants. Mass spectrum of components (left panel) and deconvoluted ion set (right panel) of each purified scaffold. a) VAO_H61T_L171K. M_{calc} : 64,079 Da; M_{obs} : 63,949 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 130$ Da). b) VAO_H61T_Y187K. M_{calc} : 64,029 Da; M_{obs} : 63,899 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 130$ Da). c) VAO_H61T_H422K. M_{calc} : 64,055 Da; M_{obs} : 63,925 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 130$ Da). d) VAO_H61T_L171pAF. M_{calc} : 64,113 Da; M_{obs} : 63,983 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 130$ Da). e) VAO_H61T_Y187pAF. M_{calc} : 63,932 Da; M_{obs} : 63,933 Da. VAO_H61T_H422pAF. M_{calc} : 64,089 Da; M_{obs} : 63,959 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 130$ Da).




Figure S10. LC-MS analysis of lysine and pAF EncP_R299K variants. Mass spectrum of components (left panel) and deconvoluted ion set (right panel) of each purified scaffold. a) EncP_R299K_Y54K. M_{calc} : 57,418 Da; M_{obs} : 57,290 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 128$ Da). b) EncP_R299K_N196K M_{calc} : 57,467 Da; M_{obs} : 57,339 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 128$ Da).




Figure S11. LC-MS analysis of lysine and pAF TOYE variants. Mass spectrum of components (left panel) and deconvoluted ion set (right panel) of each purified scaffold. a) TOYE_Y27K M_{calc} : 39,203 Da; M_{obs} : 39,075 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 128$ Da). b) TOYE_I67K M_{calc} : 39,253 Da; M_{obs} : 39,122 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 131$ Da). c) TOYE_Y168K M_{calc} : 39,203 Da; M_{obs} : 39,077 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 130$ Da). d) TOYE_Y27pAF M_{calc} : 39,237 Da; M_{obs} : 39,109 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 128$ Da). e) TOYE_I67pAF M_{calc} : 39,287 Da; M_{obs} : 39,154 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 131$ Da). f) TOYE_Y168pAF M_{calc} : 39,207 Da; M_{obs} : 39,072 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 131$ Da).




Figure S12. Preliminary small-scale conversion optimization. a) Reactions were set at pH 5.5-11 in 50 mM HEPES 150 mM NaCl solution. b) Qualitative representation of reaction using 25 μM of pyrrolidine or aniline as side-chain catalysts controls. Reactions were formulated with 1 mM *E*-cinnamaldehyde and 50 mM nitromethane.




Figure S13. SDS-PAGE of DProK variants. Purifications of scaffolds were done by immobilized metal affinity chromatography (Ni^{2+} -NTA) and affinity purification for LmrR variants (Strep-tag II): a) LmrR variants ca. MW 15 kDa, b) TOYE variants MW 38 kDa, c) VAO_H61T variants, MW 64 kDa and d) EncP_R299K variants.




Figure S14. LC-MS analysis of DProK variants. Mass spectrum of components (left panel) and deconvoluted ion set (right panel) of each purified scaffold. a) LmrR_M8DProK, M_{calc} : 15,196 Da; M_{obs} : 15,060 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 134$ Da). b) a) LmrR_V15DProK, M_{calc} : 15,155 Da; M_{obs} : 14,748 Da. Difference in mass corresponds to N-terminal methionine and 2x histidine cleavage ($\Delta 407$ Da). c) LmrR_M89DProK M_{calc} : 15.196 Da; M_{obs} : 15,060 Da. Difference in mass corresponds to N-terminal methionine cleavage ($\Delta 129$ Da). d) VAO_H61T_L171DProK, M_{calc} : 64,212 Da; M_{obs} : 64,048 Da, difference in mass corresponds to N-terminal methionine cleavage ($\Delta 129$ Da). e) TOYE_Y27DProK, M_{calc} : 39,300 Da; M_{obs} : 39,168, difference in mass corresponds to N-terminal methionine cleavage ($\Delta 132$ Da) f) TOYE_I67DProK, M_{calc} : 39,350 Da; M_{obs} : 39,214 difference in mass corresponds to N-terminal methionine cleavage ($\Delta 136$ Da) g) TOYE_Y168DProK, M_{calc} : 39,300 Da; M_{obs} : 34,172 difference in mass corresponds to N-terminal methionine cleavage ($\Delta 128$ Da).




Figure S15. TOYE as biocatalyst for Michael addition reaction. Chromatograms of small-scale conversions were performed using 25 μM TOYE, a) and b) I67DProK or c) and d) Y168 DProK at pH 6.5 in 50 mM HEPES and 150 mM NaCl buffer. Reactions were set with 1 mM *E*-cinnamaldehyde and a) and c) 50 or b) and d) 100 mM nitromethane as nucleophile. Chromatograms were manually shifted to facilitate qualitative comparison.




Figure S16. Analysis of synthesized N^6 -prolyl-*L*-lysine. Synthesis of nAA DProK was analysed by a) hydrogen and b) carbon NMR, d) LC-MS, and specific rotation (1 g 100 mL $^{-1}$ displayed +40 and +38).




Figure S17. Analytics of substrate and product. Synthesis of 4-nitro-3-phenylbutanal was performed using 5 μM DERA-MA enzyme as a biocatalyst in a 100 mL small-scale reaction. The reaction was formulated with 5 mM *E*-cinnamaldehyde, 50 mM nitromethane, in 50 mM HEPES, 150 mM NaCl, and 10% ethanol, pH 6.5. The product was obtained after flash chromatography with a 50% yield. The sample was analysed by a) GC and b) NMR. Calibration curves were used to calculate substrate depletion and *E*-cinnamaldehyde in the product sample. c) A calibration curve using commercial (Merck) *E*-cinnamaldehyde was used to calculate the remnant substrate obtained in the biosynthesis, then d) the calibration curve of the product was recalculated accordingly. Chromatograms for each concentration of substrate and product, and the residual plots of the calibration curves are shown.